ライフサイエンスコーパス: perphenazine

1 y pair of agents, including the typical drug perphenazine.

2 hotics and a first-generation antipsychotic, perphenazine.

3 yskinesia were prohibited from assignment to perphenazine.

4 ration drug, including clozapine, but not to perphenazine.

5 o receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 80

6 olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine

7 Importantly, exposure to perphenazine, a compound that induces mammary gland diff

8 as shown by the relative ineffectiveness of perphenazine, a potent mitogenic and differentiating age

9 ockdown of specific PP2A subunits attenuated perphenazine activity, indicating that PP2A mediates the

10 Furthermore, compared to perphenazine alone, PEI-P conjugates exhibit an enhanced

11 here were no significant differences between perphenazine and any second-generation medication.

12 a mediator of neurologic toxicity induced by perphenazine and related neuroleptics.

13 the combination of a typical antipsychotic (perphenazine) and a mood stabilizer (lithium, carbamazep

14 xol, olanzapine, zuclopenthixol, quetiapine, perphenazine, and methotrimeprazine.

15 hat other antipsychotic drugs (flupenthixol, perphenazine, and zotepine) also ameliorate the effects

16 cacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, ris

17 ween olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small o

18 T-ALL cell lines treated with perphenazine exhibited rapid dephosphorylation of multip

19 Finally, human T-ALLs treated with perphenazine exhibited suppressed cell growth and dephos

20 eurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidon

21 ; 95% CI, 0.48-0.58), long-acting injectable perphenazine (HR, 0.58; 95% CI, 0.52-0.65), and long-act

22 pine (HR, 0.91; 95% CI, 0.83-1.00), and oral perphenazine (HR, 0.86; 95% CI, 0.77-0.97) were associat

23 We identified the antipsychotic drug perphenazine in both screens due to its ability to induc

24 eiving prescriptions for haloperidol (N=57), perphenazine (N=60), risperidone (N=80), olanzapine (N=6

25 tment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (ol

26 eatment with adjunctive medication (lithium, perphenazine, or paroxetine) (N = 39) or did not (N = 11

27 domly assigned to receive either citalopram, perphenazine, or placebo under double-blind conditions f

28 f z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.2

29 risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group.

30 valent molecular motif, the polyethylenimine-perphenazine (PEI-P) conjugate which has a dual "acceler

31 signed to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up

32 ere randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone fo

33 Patients treated with citalopram or perphenazine showed statistically significant improvemen

34 dentified protein phosphatase 2A (PP2A) as a perphenazine target.

35 300 dollars-600 dollars (20%-30%) lower for perphenazine than for second-generation antipsychotics b

36 Perphenazine treatment had similar effects.

37 od stabilizer they received either continued perphenazine treatment or placebo.

38 Patients randomly assigned to continue perphenazine treatment, relative to those who discontinu

39 on for weight gain or metabolic effects, and perphenazine was associated with more discontinuation fo

40 Treatment with perphenazine was less costly than treatment with second-

41 th typical APDs, for example haloperidol and perphenazine, which are mainly DA D(2/)D(3) receptor ant

42 ake inhibitor citalopram and the neuroleptic perphenazine with placebo for the treatment of psychosis

43 e compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind